IBRX261204C00011000
IBRX Dec 4 2026 11.00 Call
optionOPRA
EODNov 5, 2026
0.50USD+2.041%(+0.01)90Vol484OI
Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
11
Expiration
Dec 4, 2026
DTE
21d
Moneyness
OTM
Intrinsic
$0.00
IBRX 11 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.11 | -35.29% | 7 | 663 |
| Nov 20, 2026 | 7d | $0.50 | +66.67% | 162 | 5,088 |
| Nov 27, 2026 | 14d | $0.35 | -30.00% | 11 | 90 |
| Dec 4, 2026 | 21d | $0.50 | +2.04% | 90 | 484 |
| Dec 11, 2026 | 28d | — | — | 0 | 4 |
| Dec 18, 2026 | 35d | $0.60 | +0.00% | 10 | 136 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.75 | -1.32% | 35 | 11,543 |
| Mar 19, 2027 | 126d | $1.17 | -16.43% | 2 | 915 |
| Apr 16, 2027 | 154d | $1.17 | -52.82% | 1 | 102 |
| May 21, 2027 | 189d | $1.50 | -50.00% | 10 | 32 |
IBRX Nearby Strikes · Dec 4, 2026
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.